Navigation Links
Protalix BioTherapeutics to Present at UBS Global Life Sciences Conference
Date:9/19/2007

CARMIEL, Israel, Sept. 19 /PRNewswire-FirstCall/ -- Protalix BioTherapeutics, Inc. (Amex: PLX), today announced that Dr. David Aviezer, its President and Chief Executive Officer, will present at the UBS Global Life Sciences Conference at the Grand Hyatt New York on Monday, September 24, 2007, at 9:30 a.m. EDT.

The Company's presentation can be accessed live via webcast at http://events.streamx.us/us/event/eventdetails.aspx?id=ubs20070924. Following the live presentation, the archived webcast will be available for a period of 30 days.

About Protalix BioTherapeutics, Inc.

Protalix is a clinical stage biopharmaceutical company. Its goal is to become a fully integrated biopharmaceutical company focused on focused on the development and commercialization of proprietary recombinant therapeutic proteins to be expressed through its proprietary plant cell based protein expression system, ProCellEx(TM). ProCellEx presents a proprietary method for the expression of recombinant proteins that Protalix believes is safe and scalable and will allow for the cost-effective, industrial-scale production of recombinant therapeutic proteins. Protalix has initiated enrollment and treatment of patients in its pivotal phase III clinical trial of its lead product candidate, prGCD, for enzyme replacement therapy of Gaucher disease, a lysosomal storage disorder in humans. The final design of the pivotal phase III clinical trial is based on an agreement reached by Protalix with the United States Food and Drug Administration, through its Special Protocol Assessment (SPA). Protalix is also advancing additional recombinant biopharmaceutica
'/>"/>

SOURCE Protalix BioTherapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2014)... With a larger, brighter interface, ... Cole-Parmer® Digital Gear Pump Drive for Micropump® ... for automated process applications. , Simply set time ... count function counts down and displays batches completed ... dispensed across multiple cycles. View the four operating ...
(Date:7/21/2014)... (July 21, 2014) The yield so far ... have developed a low-energy, solution-based mineral substitution process to ... find use in electronics and alternative energy devices. , ... cover of the July 21 issue of the journal ... of research in the inorganic and nuclear chemistry fields. ...
(Date:7/21/2014)... Sleep disturbances such as insomnia, hypersomnia, ... depression. According to a study published by the ... of depressed patients have insomnia symptoms, and hypersomnia ... adults and 10% of older patients, with a ... have a major impact on quality of life, ...
(Date:7/19/2014)... 20, 2014 United States Non-Vascular ... GlobalDatas new report, "United States Non-Vascular Stents Market ... the United States Non-Vascular Stents market. The report ... (in units) and average prices (in US dollars) ... Stents and Metal Biliary Stents (Metal Non-Covered Biliary ...
Breaking Biology Technology:New Easy-View Cole-Parmer Digital Gear Pump Drive Makes Performance Monitoring Effortless 2Oregon chemists eye improved thin films with metal substitution 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 2Open Label Data on Enhanced Sleep Released by JayMac Pharmaceuticals, LLC 3United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 2United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 3United States Non-Vascular Stents Market Outlook to 2020 | Researchmoz 4
... Pharmaceuticals, Inc. (NYSE Amex: ANX ) today ... ended December 31, 2008."2008 was a transition year for ... focused on lower-risk reformulations of previously-approved drugs. We achieved ... the difficult economic environment, we were unable to attract ...
... Insmed Inc. (Nasdaq: INSM ), a developer of ... March 23, 2009, NASDAQ issued a notice further extending the ... price and those rules requiring a minimum market value of ... effect through Friday, July 17, 2009, and the original rules ...
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ... patient enrolment in its U.K. clinical trial to ... REOLYSIN(R) in combination with gemcitabine (Gemzar(R)) in patients ... neck. The principal investigators are Dr. Johann de ...
Cached Biology Technology:ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 2ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 3ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 4ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 5ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 6ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results 7Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 3
(Date:7/22/2014)... -- Stem cells offer much promise for treating damaged ... cell survival is poor, limiting their effectiveness. New methods ... and optimize their therapeutic function after transplantation, as described ... , a peer-reviewed journal from Mary Ann Liebert, Inc., ... BioResearch Open Access website . , ...
(Date:7/22/2014)... research has shown squirrels have adapted to New York ... well, if not better, than their fellow squirrels in ... Curtin,s Department of Environment & Agriculture, led the study ... their behaviour in urban environments and prevent unnecessary responses ... staying on the footpath. , "As we rapidly ...
(Date:7/22/2014)... of meerkats which sees them prevent their daughters from ... new study. , Research into the desert creatures which ... adult helpers shows that the alpha female can flourish ... study shows how this way of life, also found in ... despite its sinister side. , Dominant meerkats control breeding ...
Breaking Biology News(10 mins):New York squirrels are nuts about city life 2
... novel,vaccine that uses immune cells as factories to produce ... breast cancers, say researchers at,The University of Texas M. ... is a protein often present / surexpressed in ... Breast Cancer Research,on Nov. 29, 2004, showed that the ...
... NGEN), developer of advanced diagnostic products, announced today that ... Biologic Array" by the U.S. Patent and Trademark Office. ... one or more electrodes (or "test sites") across multiple ... covers a method for storing the value of the ...
... the Dana-Farber Cancer Institute report a surprising finding about ... only in the embryo itself, but also in the ... , Meticulous experiments in mice revealed that the placenta ... These cells, which appear very early in development, are ...
Cached Biology News:Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer 2Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer 3Nanogen Issued Patent for Electronic Microarray With Memory 2Placenta Is A Rich Source Of Blood Stem Cells 2
... anti-phospho-IRS1 (Tyr896) ... amino acid region encompassing the ... (Tyr896). Accession ... Quality Assurance: Routinely ...
Mouse monoclonal [YLI-90] to Ly49I (Biotin) ( Abpromise for all tested applications)....
CCNI Antibody...
Mouse monoclonal [LH8] to Cytokeratin 5 + 14 ( Abpromise for all tested applications). entrezGeneID: 3852 SwissProtID: P02533...
Biology Products: